Britain and America have finalized a landmark bilateral deal that will maintain zero tariffs on UK pharmaceutical shipments being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the NHS. This pledge guarantees that tariffs on these vital exports will remain at nothing for a timeframe of 36 months.
This agreement is in response to previous statements to dramatically increase duties on patented pharmaceutical imports, with potential rates mentioned reaching one hundred percent.
"This agreement with the Britain reinforces the global environment for innovative medicines and establishes much-needed balance to American-British medicine commerce," a statement said.
Commercial Impact
Medicines are one of the UK's largest exports to the America, which is easily the biggest buyer for major UK drugmakers.
Trade data show that in the year to the end of last September, the UK sold medicines worth £11.1bn to the US. This amount represented a significant portion of total UK exports in that period.
"This guarantee secures work, boosts investment and paves the way for the UK to become a global hub for biotech and pharma," a minister commented.
Specific UK Commitments
The pact includes several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to increase overall NHS spending on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must pay back to the NHS to stay within budget will be capped at 15%. Last year, rebates topped twenty percent.
Recent Tensions
The pact takes place against a ongoing tension between the sector and the UK government over medicine costs and NHS adoption.
These tensions were exacerbated by arguments that US customers were charged a premium for the equivalent treatments than consumers in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been directed toward American operations.
The Science Minister publicly accepted that the NHS must spend more on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the previous ten-year period.
